In a significant stride for its complex drug portfolio, Biocon has secured USFDA approval for Liraglutide injections, a key GLP-1 therapy for treating diabetes and obesity. While the drug represents ...

Biocon has launch of its GLP-1 peptide, liraglutide, for diabetes (gVictoza) and obesity (gSaxenda), in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Biocon's generics business contributed 18% to overall revenue, rising 24% year-on-year to ₹774 crore in the September quarter. Weight-loss and diabetes drugs such as semaglutide and liraglutide are ...

Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the ...

As Biocon prepares for a leadership transition beyond founder Kiran Mazumdar-Shaw, the Bengaluru-based biopharmaceutical company says years of investment in biosimilars, insulins and GLP-1 therapies ...

Biocon managing director and chief executive officer Siddharth Mittal. Biocon is betting big on GLP-1 therapies and peptides to drive its next wave of growth, as global demand for weight-loss and ...

Earnings call Biocon reported Q3 FY26 operating revenue of INR 4,173 crore, up 9% YoY, led by 9% growth in biosimilars and 24% growth in generics, offsetting a 3% decline in CRDMO. Core EBITDA rose 21 ...

Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy and ...

Did our AI summary help? Biocon is aiming for high-double-digit percentage revenue growth as the Indian pharmaceutical firm prepares to launch generic versions of weight-loss drugs globally even as it ...